Summit Therapeutics (SMMT) Debt to Equity (2022 - 2024)
Summit Therapeutics (SMMT) has disclosed Debt to Equity for 4 consecutive years, with $2.26 as the latest value for Q1 2024.
- For the quarter ending Q1 2024, Debt to Equity rose 201.93% year-over-year to $2.26, compared with a TTM value of $2.26 through Mar 2024, up 201.93%, and an annual FY2023 reading of $1.29, down 67.04% over the prior year.
- Debt to Equity was $2.26 for Q1 2024 at Summit Therapeutics, up from $1.29 in the prior quarter.
- Across five years, Debt to Equity topped out at $3.9 in Q4 2022 and bottomed at $0.39 in Q1 2022.
- Average Debt to Equity over 3 years is $1.42, with a median of $0.84 recorded in 2023.
- The sharpest move saw Debt to Equity tumbled 67.04% in 2023, then surged 201.93% in 2024.
- Year by year, Debt to Equity stood at $3.9 in 2022, then crashed by 67.04% to $1.29 in 2023, then surged by 75.73% to $2.26 in 2024.
- Business Quant data shows Debt to Equity for SMMT at $2.26 in Q1 2024, $1.29 in Q4 2023, and $0.84 in Q2 2023.